Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia (Q34112932)

31 July 2017

1 reference

title

Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia (English)

1 reference

31 July 2017

0 references

G L Plosker

1

1 reference

31 July 2017

C I Dunn

series ordinal

2

1 reference

31 July 2017

D P Figgitt

series ordinal

3

1 reference

31 July 2017

publication date

1 November 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

60

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

1179-1206

1 reference

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

31 July 2017

cites work

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions

1 reference

12 December 2020

International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group.

1 reference

12 December 2020

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Influence of cholestyramine on the pharmacokinetics of cerivastatin.

1 reference

12 December 2020

Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers

1 reference

12 December 2020

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

1 reference

12 December 2020

Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment

1 reference

12 December 2020

Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits

1 reference

12 December 2020

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy

1 reference

12 December 2020

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

12 December 2020

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

12 December 2020

Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation

1 reference

12 December 2020

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

1 reference

12 December 2020

Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies

1 reference

12 December 2020

Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers

1 reference

12 December 2020

Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth

1 reference

12 December 2020

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

12 December 2020

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

1 reference

12 December 2020

Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil.

1 reference

12 December 2020

Maximizing the cost-effectiveness of lipid-lowering therapy

1 reference

12 December 2020

New insights into plaque stabilisation by lipid lowering.

1 reference

12 December 2020

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia

1 reference

12 December 2020

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients

1 reference

12 December 2020

Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition

1 reference

12 December 2020

Pharmacokinetics of fluvastatin and specific drug interactions

1 reference

12 December 2020

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

1 reference

12 December 2020

1 reference

12 December 2020

Cerivastatin-induced rhabdomyolysis

1 reference

12 December 2020

Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia

1 reference

12 December 2020

The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man.

1 reference

12 December 2020

Epidemiology of hypercholesterolemia and European management guidelines

1 reference

12 December 2020

Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. Hyperlipidaemia in Diabetes Mellitus investigators

1 reference

12 December 2020

HMG-CoA reductase inhibitors and myotoxicity

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Cost effectiveness of coronary heart disease prevention strategies in adults

1 reference

12 December 2020

Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.

1 reference

12 December 2020

Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin

1 reference

12 December 2020

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

12 December 2020

Management of hypercholesterolemia

1 reference

12 December 2020

Control of lipid disorders in patients with atherosclerotic vascular disease

1 reference

12 December 2020

A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia

1 reference

12 December 2020

Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor

1 reference

12 December 2020

Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study. Cerivastatin Study Group

1 reference

12 December 2020

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

1 reference

12 December 2020

Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes

1 reference

12 December 2020

No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and Warfarin

1 reference

12 December 2020

Lack of drug-drug interaction between cerivastatin and nifedipine.

1 reference

12 December 2020

Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group

1 reference

12 December 2020

Effect of itraconazole on cerivastatin pharmacokinetics

1 reference

12 December 2020

Clinical pharmacokinetics of pravastatin

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures

1 reference

12 December 2020

Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance

1 reference

12 December 2020

Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin

1 reference

12 December 2020

Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.

1 reference

12 December 2020

Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.

1 reference

12 December 2020

Clinical pharmacokinetics of cerivastatin

1 reference

12 December 2020

Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

12 December 2020

Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

10.2165/00003495-200060050-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1000331156

0 references

1 reference